Atrial Fibrillation – Resources for Providers
In 2019, Afib was mentioned on 183,321 death certificates and was the underlying cause in 26,535 of those deaths.
Research on Atrial Fibrillation
Racial and Ethnic Considerations in Patients With Atrial Fibrillation: JACC Focus Seminar 5/9
Atrial Fibrillation: JACC Council Perspectives
Anticoagulant Therapy Toolkit
Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic Minorities
Relative contribution of modifiable risk factors for incident atrial fibrillation in Hispanics, African Americans and non-Hispanic Whites
A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial
Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association
Integrated Care in Atrial Fibrillation
In 2020, The Bristol Myers Squibb (BMS)-Pfizer Alliance launched the No Time to Wait campaign to raise awareness on the symptoms of atrial fibrillation. As part of this campaign, basketball icon Kareem Abdul-Jabbar partnered with BMS and Pfizer to shared his experience with Afib and what lead to his diagnosis. You can access the full press release here.